Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Imunon, Inc. Common Stock

IMNN

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Last trade $0.61
Day change +$0.016 (+2.69%)
Day range $0.568 – $0.622
Volume 86,266
Market cap $4M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.83M
Price / earnings
—
Price / book
1.46×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.41×

Profitability

Earnings per share
-$2.32
Return on assets
-125.36%
Return on equity
-574.08%
Dividend yield
0%

Liquidity and leverage

Debt / equity
2.38×
Current ratio
1.38×
Quick ratio
1.38×
Cash ratio
0.95×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.95M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IMNN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.66M$1.33M$1.97M$1.77M$1.58M$1.54M$1.98M$1.91M
Research and development$1.79M$1.46M$2.34M$2.49M$1.9M$1.23M$2.17M$2.23M
Total operating expenses$3.45M$2.79M$4.31M$4.26M$3.48M$2.77M$4.15M$4.15M
Operating income-$3.45M-$2.79M-$4.31M-$4.26M-$3.48M-$2.77M-$4.15M-$4.15M
Interest expense-$264.13K-$77.27K$0$0$0$0$0$0
Income before taxes-$3.75M-$2.81M-$4.25M-$4.22M-$3.43M-$2.74M-$4.1M-$4.06M
Income taxes$0$0$0$0$0$0$0$0
Net income-$3.75M-$2.81M-$4.25M-$4.22M-$3.43M-$2.74M-$4.1M-$4.06M
Net income attributable to common shareholders-$3.75M-$2.83M-$4.25M-$4.22M-$3.43M-$2.74M-$4.1M-$4.06M
EBITDA-$3.38M-$2.72M-$4.24M-$4.19M-$3.4M-$2.69M-$4.08M-$4.11M
Basic earnings per share-$0.64-$0.54-$0.84-$1.42-$1.16-$2.15-$3.15-$2.44
Diluted earnings per share-$0.64-$0.54-$0.84-$1.42-$1.16-$2.15-$3.15-$2.44

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

IMUNON reported Q3 2026 financial results with a net loss of $3.8 million. The company highlighted progress in its Phase 3 OVATION 3 trial of IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer, with enrollment expected to complete by Q1 2029. Recent developments include a collaboration with the National Cancer Institute, positive Phase 2 data showing overall survival benefits, and strategic moves to strengthen financial position including transitioning ThermoDox to VoxelDox and completing a debt-for-equity exchange.

GlobeNewswire Inc.

IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer

IMUNON announced new translational data from its Phase 2 OVATION 2 study showing that IMNN-001, when combined with standard chemotherapy, increased anti-tumor T-cell activity and improved median overall survival by 14.7 months in advanced ovarian cancer patients. The data demonstrates the drug's mechanism of converting the tumor microenvironment from immunologically 'cold' to 'hot,' supporting the ongoing Phase 3 OVATION 3 trial.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 7, 20251.15-for-1stock dividend
Jul 25, 20251-for-15reverse split
Mar 1, 20221-for-15reverse split
May 30, 20171-for-14reverse split
Oct 29, 20131-for-4.5reverse split